TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT03688087

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Smartphone application placebo
Description: Strategy based on smartphone application placebo

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Smartphone equipped with application bouge = Coach group
Description: Strategy based on smartphone application bouge
Study: NCT01236898

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NPC-09
Description: NPC-09 tablet NPC-09 contains 50mg or 100mg N-acetylneuraminic acid (anhydride)
Study: NCT04349709

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Brief school-based DBT-A
Description: The intervention is inspired to Dialectical Behavior Therapy for Adolescents (DBT-A) (Rathus \& Miller, 2015, Mazza et al, 2016; Cappelluccio, 2019). It consists in four monthly 2-hour sessions (for a total of 8 hours) scheduled during school-time. All the sessions are conducted by two psychotherapists trained about DBT. During the sessions, the model of emotions is described through a role-play between conductors. Subsequently, teens are trained about main emotional regulation skills. Moreover, basic elements of distress tolerance, mindfulness and interpersonal efficacy are introduced too.
Study: NCT03060785

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tenofovir Disoproxil Fumarate/Emtricitabine

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tenofovir Disoproxil Fumarate/Emtricitabine
Study: NCT02605876

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Whole body vibration

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Local muscle vibration
Study: NCT00996242

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: L-lysine
Description: 6 g/day for four weeks
Study: NCT00689637

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD3480
Description: AZD3480 capsules qd, 12 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo capsules qd, 12 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Warfarin
Description: Warfarin: single dose on day 6

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Warfarin
Description: Warfarin: single dose on day 6
Study: NCT03741985

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: The handgrip exercise
Description: The control group was given routine dialysis treatment and daily handgrip exercise .Patients are asked to squeeze a rubber ring 30 times per min for altogether 20 minutes on non-dialysis days.The 20-minute exercise can be divided into 3 parts according to individual circumstances.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: The dumbbell exercise
Description: The experimental group was given routine dialysis treatment and daily dumbbell exercise .Patients are asked to hold 6-pound dumbbells to exercise 30 times per min for altogether 20 minutes on non-dialysis days.The 20-minute exercise can be divided into 3 parts according to individual circumstances.
Study: NCT03389516

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Polymem
Description: wound care dressings
Study: NCT03237026

Intervention type: OTHER
Intervention: No intervention required
Description: No intervention required

Intervention type: OTHER
Intervention: No intervention required
Description: No intervention required
Study: NCT01916057

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: 18F-FDG PET Scan
Description: to determine whether F18 fluorodeoxyglucose (18F-FDG) positron-emission tomography scan (PET scan) is useful for the therapy strategy of hepatosplenic candidiasis.
Study: NCT00847197

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MK1903
Description: Three 50 mg capsules MK1903 by mouth every 8 hours for 4 weeks. All participants will receive placebo for a 2 week run-in period.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Comparator: Placebo
Description: Three 50 mg capsules placebo to MK1903 every 8 hours for 4 weeks. All participants will receive placebo for a 2 week run-in period.
Study: NCT01906528

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mivacurium
Description: Effect of Mivacurium in males vs females
Study: NCT02395692

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Treatment
Description: Correlative studies

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methoxyamine
Description: Given PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Temozolomide
Description: Given PO
Study: NCT02979678

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaire
Description: The questionnaire should be updated with respect to wording, terminology.
Study: NCT03966456

Intervention type: DRUG
Intervention: Chemotherapy
Description: compare the effecy and safety of 4 PD-1 agents single and combined with chemotherapy in chinese people.

Intervention type: DRUG
Intervention: Chemotherapy
Description: compare the effecy and safety of 4 PD-1 agents single and combined with chemotherapy in chinese people.

Intervention type: DRUG
Intervention: Chemotherapy
Description: compare the effecy and safety of 4 PD-1 agents single and combined with chemotherapy in chinese people.

Intervention type: DRUG
Intervention: Chemotherapy
Description: compare the effecy and safety of 4 PD-1 agents single and combined with chemotherapy in chinese people.
Study: NCT00637559

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Esomeprazole Magnesium

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Esomeprazole Magnesium

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Esomeprazole Magnesium
Study: NCT02374372

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: conventional hemodialysis
Study: NCT01098526

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK1349572
Description: GSK1349572 is an experimental drug under development for the treatment of HIV. It is in the class of integrase inhibitors.
Study: NCT02374372

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: hemodiafiltration On-line
Study: NCT03389516

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Lanolin
Description: wound care oinment
Study: NCT01286753

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vemurafenib
Description: Vemurafenib 960 mg orally twice daily.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vemurafenib
Description: Vemurafenib 960 mg orally twice daily.
Study: NCT02986867

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: SAbR Treatment of Lesions
Description: SAbR will be administered as per the guidelines of UTSW with a single 24-27Gy or three 10-14 Gy/fraction fractions totaling 33-48Gy. Lesions receiving SAbR will be called radiated lesions.
Study: NCT01098526

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Efavirenz
Description: Efavirenz is a drug that has been approved by the FDA for the treatment of HIV. It is in the class of non-nucleoside reverse trancriptase inhibitors.
Study: NCT02829645

Intervention type: OTHER
Group type: OTHER
Intervention: Clinical assessment
Description: Clinical assessment with questionnaires
Study: NCT02422134

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Cytokine group
Description: Testing the efficacy of adding Cytokine to embryo transfer medium
Study: NCT00153972

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cabergoline
Study: NCT02497690

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Telemedicine
Description: Half of subjects will undergo six months of ART administered via telehealth. Therapy will be provided in the usual manner, except a computer will be used to facilitate the interaction.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: In-person ART
Description: Half of subjects will undergo six months of ART administered in person. Therapy will be provided in the usual manner.
Study: NCT04518683

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Perineal rehabilitation with mobile applications for women with SUI
Description: Physiotherapy: Sessions with the physiotherapist will consist of information on anatomy, perineal awareness and behavioural therapy. The therapist will educate the patient on pelvic floor contraction/relaxation. the sessions will remain personalized and standardized like a classic treatment, and will also aim to work on motivation. 9 sessions during 3 months.~Home Program: The home program will be done with a mobile application equipped with a vaginal probe. The exercises should be done 3x/week for 10 minutes. The correct use of the prob will have been checked during the sessions with the physiotherapist. This training will work on the strength, relaxation and endurance of the pelvic floor.The program includes 3 levels of difficulty. Once the user has successfully completed one level, she can move on to the next.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Classic perineal rehabilitation for women with SUI
Description: Physiotherapy: Sessions with the physiotherapist will consist of information on anatomy, perineal awareness and behavioural therapy. The therapist will educate the patient on pelvic floor contraction/relaxation. The sessions will remain personalized and standardized like a classic treatment, and will also aim to work on motivation. 9 sessions during 3 months.~Home program: The home program will be done without a mobile application. The exercises will have been explained during the sessions with the physiotherapist by oral instructions. The exercises will be done 3x/week for 10 minutes. The correct realization of the exercises will have been verified during the sessions with the physiotherapist.
Study: NCT04434014

Intervention type: DIETARY_SUPPLEMENT
Intervention: proper diet
Description: diet containing all essential vitamins

Intervention type: DIETARY_SUPPLEMENT
Intervention: proper diet
Description: diet containing all essential vitamins
Study: NCT00223704

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HOE 140
Description: HOE 140 (a bradykinin B2 receptor antagonist) was started in the operating room after induction of anesthesia and before heparinization, continued throughout the bypass period, and discontinued at the end of surgery. HOE 140 was given as an intravenous bolus of 22 µg/kg over one-half hour followed by an infusion of 18 µg/kg/hr.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Aminocaproic Acid
Description: Aminocaproic acid (an antifibrinolytic drug) was started in the operating room after induction of anesthesia and before heparinization, continued throughout the bypass period, and discontinued at the end of surgery. Aminocaproic acid was given as an intravenous bolus of 100 mg/kg over one-half hour followed by an infusion of 30 mg/kg/hr.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Normal saline (placebo) was started in the operating room after induction of anesthesia and before heparinization, continued throughout the bypass period, and discontinued at the end of surgery.
Study: NCT05182268

Intervention type: PROCEDURE
Intervention: endoscopic ear surgery
Description: a ear surgery via endoscopic

Intervention type: PROCEDURE
Intervention: microscopic ear surgery
Description: a ear surgery via microscopic
Study: NCT00153972

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cabergoline

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Levodopa

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Levodopa
Study: NCT02229461

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Naproxen Sodium (Aleve, BAY117031)
Description: Naproxen sodium 220 mg qd or bid

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Naproxen Sodium (Aleve, BAY117031)
Description: Naproxen sodium 220 mg qd or bid
Study: NCT02113332

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Liraglutide

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT02687581

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: IO-therapy Glasses
Description: 12-hour of 50% intermittent occlusion therapy on the fellow eye.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: patch
Description: 6-hour of eye patch on the fellow eye
Study: NCT00289081

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Total Knee Replacement
Description: Rotating Platform (RP) Cruciate Retaining Knee implant

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Total knee replacement
Description: Rotating Platform (RP) Cruciate Substituting Knee implant.
Study: NCT01440205

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Easy list of healthy habits
Description: The recipient will be prompted to check off yes or no to healthy habits that most people will find fairly easy.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Challenging list of healthy habits
Description: The recipient will be prompted to check off yes or no to healthy habits that most people will find fairly difficult.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Control
Description: No check box element
Study: NCT02305238

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aflibercept (Eylea, VEGF Trap-Eye, BAY86-5321)
Description: Aflibercept 2mg is intravitreally injected.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aflibercept (Eylea, VEGF Trap-Eye, BAY86-5321)
Description: Aflibercept 2mg is intravitreally injected.
Study: NCT04379076

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Interleukin-7
Description: Intramuscular (IM) administration of CYT107 at 3 μg/kg followed, after 48hrs of observation, by 10 μg/kg twice a week for 2 weeks or

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebos
Description: Intramuscular (IM) placebo (normal saline) at the same frequency
Study: NCT01694836

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: s.c. injection
Description: 3 years of therapy followed by 2 years (seasons) of treatment-free observational period

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: s.c. injection
Description: 3 years of therapy followed by 2 years (seasons) of treatment-free observational period
Study: NCT01898013

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pregnenolone

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT02372981

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: mucopexy +/- Doppler-guided haemorrhoidal artery ligation
Description: Mucopexy with or without DG-HAL is performed using a specific device consisting of a proctoscope equipped with a Doppler probe and a light source. The proctoscope model in our study has a sliding part comprising the operating window and Doppler probe for better proximal and distal movement without repositioning the proctoscope during mucopexy.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: mucopexy +/- Doppler-guided haemorrhoidal artery ligation
Description: Mucopexy with or without DG-HAL is performed using a specific device consisting of a proctoscope equipped with a Doppler probe and a light source. The proctoscope model in our study has a sliding part comprising the operating window and Doppler probe for better proximal and distal movement without repositioning the proctoscope during mucopexy.
Study: NCT04450095

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ambrisentan 10 MG
Description: be given once a day for 5 days, starting 48 hours before surgery
Study: NCT02316886

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Coronary intervention
Description: bioabsorbable vascular scaffolds (BVS) (early period) or everolimus-eluting stents (middle and late period) + Optimal Medical Treatment

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Optimal Medical treatment
Study: NCT01068158

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 0.5% Ivermectin Cream
Description: Up to 4 ounces of 0.5% Ivermectin Cream applied to hair and scalp on day 1.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo control
Description: up to 4 ounces of topical vehicle control to head and scalp on day 1.
Study: NCT00772499

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: olmesartan medoxomil + hydrochlorothiazide + amlodipine + hydralazine if necessary to control blood pressure
Description: Tablets and capsules for oral administration once or twice daily for up to 52 weeks
Study: NCT03865784

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Experimental
Description: The intervention through Core exercises will consist in the application of a protocol of four Core stabilization exercises. This protocol will consist of the following exercises: abdominal plate, bilateral plate, hunting dog and gluteal bridge. The intervention by Kinesiotape will be performed with the subject in a sitting position with both arms relaxed throughout the body, while the physiotherapist will place the bases of the strips without tension, on the sacroiliac joint. Once this is done, proceed to ask the subject to lean forward applying the rest of the strip, except the distal edge, with a tension of between 15 and 25%, finally requesting the subject to rejoin straining the distal base without tension, on the twelfth dorsal spinous process.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Control
Description: The intervention through Core exercises will consist in the application of a protocol of four Core stabilization exercises. The objective of the application of the technique based on this type of exercise is to improve muscle strength, endurance and neuromuscular control. This protocol will consist of the following exercises: abdominal plate, bilateral plate, hunting dog and gluteal bridge. The intervention by Kinesiotape will be performed with the subject in a sitting position with both arms relaxed throughout the body, while the physiotherapist will place the bases of the strips without tension, on the sacroiliac joint. Once this is done the tape will be placed without tension and sn movement of the subject.
Study: NCT02999412

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Comprehensive medication review
Description: * A thorough medication reconciliation, including a patient/carer interview, by a clinical pharmacist.~* The clinical pharmacist performs a comprehensive medication review in collaboration with the ward physician and patient, similar to a level three clinical medication review as earlier described in the literature \[4\]. This includes a structured, critical examination of all of the patient's medications in relation to the patient's conditions, based on information from the patient and the medical record. The objective is to optimise the impact of medications and minimizing the number of medication-related problems. The effects of medication changes will be monitored during the hospital stay by the physician or pharmacist, depending on the specific situation.~* Before discharge, the clinical pharmacist performs another medication reconciliation to check if the patient's prescriptions for medications to be used after hospital stay are consistent with the patient's medical record.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Comprehensive medication review with active follow-up
Description: The same as I1 but with the following additions:~* In case of any monitoring needs or necessary subsequent actions to be taken after hospital discharge, the clinical pharmacist and the ward physician send an electronic medication review referral to the patient's primary care physician upon discharge.~* A first phone call to the patient or carer is made by the clinical pharmacist 2-7 days after the patient is discharged depending on health condition and the pharmacist's availability. This phone call aims to ensure that all information has been understood correctly and to find out if any problems, concerns or questions have arisen after discharge.~* A second phone call will be made by the clinical pharmacist approximately 30 days after hospital discharge. This phone call aims to find out how the patient is managing the medication and if any problems, concerns or questions have arisen, and to provide the patient with a motivational boost.

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Usual Care
Description: The control group will receive usual hospital care. According to Swedish legislation, usual care includes medication reconciliation upon admission. Next to that, the law requires a medication report addressing the patient's medication treatment to be given to the patient or carer upon hospital discharge and to be attached to the electronic discharge letter. This report contains a motivation and explanation to the changes in medication treatment that have been made during hospital stay, as well as the patient's updated medication list. These mandatory activities are currently carried out to various degree within the different hospitals and wards. Other activities as described in the interventions above may be carried out to a certain degree as well, but no clinical pharmacist will be involved.
Study: NCT02741206

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Bellevue ROSE Intervention

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Bellevue ROSE Intervention

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Psycho-education session and usual, Standard of care Control
Description: Psycho Education and usual, standard of care

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Psycho-education session and usual, Standard of care Control
Description: Psycho Education and usual, standard of care

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: One Psycho-education session and usual, standard of care Control
Study: NCT02861859

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Olanzapine
Description: Olanzapine 5 mg (2 x 2.5 mg) PO OD (once a day) on days 1-4.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Olanzapine Placebo
Description: Olanzapine Placebo 5 mg (2 x 2.5 mg) PO OD (once a day) on days 1-4.
Study: NCT01955538

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Control
Description: Psychiatric treatment as usual for 6 months according to best clinical practice.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Basic Body Awareness Therapy
Description: 20 weeks, 1 hour/week.
Study: NCT00772499

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: atenolol+ hydrochlorothiazide + amlodipine + hydralazine if necessary to control blood pressure
Description: Tablets and capsules for oral administration once or twice daily for up to 52 weeks
Study: NCT01955538

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Basic Body Awareness Therapy
Description: 20 weeks, 1 hour/week.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Mixed physical activity
Description: 20 weeks, 1 hour/week.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Mixed physical activity
Description: 20 weeks, 1 hour/week.